Terms: = Germ cell tumor AND CALR, ENSG00000179218, 811, P27797, SSA, RO, FLJ26680, cC1qR
565 results:
1. [Fully Automatic Glioma Segmentation Algorithm of Magnetic Resonance Imaging Based on 3D-UNet With More Global Contextual Feature Extraction: An Improvement on Insufficient Extraction of Global Features].
Tian H; Wang Y; Ji Y; Rahman MM
Sichuan Da Xue Xue Bao Yi Xue Ban; 2024 Mar; 55(2):447-454. PubMed ID: 38645864
[TBL] [Abstract] [Full Text] [Related]
2. Advancements in medical treatment for pancreatic neuroendocrine tumors: A beacon of hope.
Giri S; Sahoo J
World J Gastroenterol; 2024 Mar; 30(12):1670-1675. PubMed ID: 38617746
[TBL] [Abstract] [Full Text] [Related]
3. The association between calreticulin and glucagon-like peptide-1 expressions with prognostic factors in high-grade gliomas.
Baran O; Akgun MY; Kayhan A; Evran S; Ozbek A; Akyoldas G; Samanci MY; Demirel N; Sonmez D; Serin H; Kocak A; Kemerdere R; Tanriverdi T
J Cancer Res Ther; 2024 Jan; 20(1):25-32. PubMed ID: 38554294
[TBL] [Abstract] [Full Text] [Related]
4. IL-12-Overexpressed Nanoparticles Suppress the Proliferation of Melanoma Through Inducing ICD and Activating DC, CD8
Shen HH; Peng JF; Wang RR; Wang PY; Zhang JX; Sun HF; Liang Y; Li YM; Xue JN; Li YJ; Sun GB; Xie SY
Int J Nanomedicine; 2024; 19():2755-2772. PubMed ID: 38525008
[TBL] [Abstract] [Full Text] [Related]
5. The global leadership into malnutrition criteria reveals a high percentage of malnutrition which influences overall survival in patients with gastroenteropancreatic neuroendocrine tumours.
Clement DSVM; van Leerdam ME; Tesselaar MET; Cananea E; Martin W; Weickert MO; Sarker D; Ramage JK; Srirajaskanthan R
J Neuroendocrinol; 2024 Apr; 36(4):e13376. PubMed ID: 38389192
[TBL] [Abstract] [Full Text] [Related]
6. Personalized treatment of well-differentiated gastric neuroendocrine tumors based on clinicopathological classification and grading: A multicenter retrospective study.
Huang J; Liu H; Yang D; Xu T; Wang J; Li J
Chin Med J (Engl); 2024 Mar; 137(6):720-728. PubMed ID: 38384175
[TBL] [Abstract] [Full Text] [Related]
7. Treatment modalities favoring outcome in well-differentiated neuroendocrine tumors G3.
Hinterleitner M; Pfeiffer R; Trautwein NF; Sipos B; Singer S; Nadalin S; Königsrainer A; Lauer UM; la Fougère C; Zender L; Hinterleitner C
Front Endocrinol (Lausanne); 2023; 14():1285529. PubMed ID: 38260136
[TBL] [Abstract] [Full Text] [Related]
8. The Establishment and Verification of a Nomogram Model for Predicting the Overall Survival of Medullary Thyroid Carcinoma: An Analysis Based on the SEER Database.
Wang W; Wang X; Che G; Qiao J; Chen Z; Liu J
Curr Oncol; 2023 Dec; 31(1):84-96. PubMed ID: 38248091
[TBL] [Abstract] [Full Text] [Related]
9. Sequencing of Somatostatin-Receptor-Based Therapies in Neuroendocrine tumor Patients.
Strosberg JR; Al-Toubah T; El-Haddad G; Reidy Lagunes D; Bodei L
J Nucl Med; 2024 Mar; 65(3):340-348. PubMed ID: 38238038
[TBL] [Abstract] [Full Text] [Related]
10. The impact of prognostic factors and comorbidities on survival in older adults with stage I - III cutaneous melanoma in Southwest Finland: A register study.
Mattila KE; Vihinen H; Heervä E; Nuotio MS; Vihinen P
J Geriatr Oncol; 2024 Mar; 15(2):101701. PubMed ID: 38219332
[TBL] [Abstract] [Full Text] [Related]
11. Long non-coding RNA as a potential diagnostic and prognostic biomarker in melanoma: A systematic review and meta-analysis.
Masrour M; Khanmohammadi S; Fallahtafti P; Hashemi SM; Rezaei N
J Cell Mol Med; 2024 Feb; 28(3):e18109. PubMed ID: 38193829
[TBL] [Abstract] [Full Text] [Related]
12. Real-world management practices and characteristics of patients with advanced melanoma initiated on immuno-oncology or targeted therapy in the first-line setting during the period 2015-2018 in Greece. The 'SUMMER' study: a retrospective multicenter chart review project.
Bafaloukos D; Kouzis P; Gouveris P; Boukovinas I; Kalbakis K; Baka S; Kyriakakis G; Moschou D; Molfeta A; Demiri S; Mavroudis D; Spanoudi F; Dimitriadis I; Gogas H
Melanoma Res; 2024 Apr; 34(2):152-165. PubMed ID: 38092014
[TBL] [Abstract] [Full Text] [Related]
13. Clinical impact of unsuccessful subcutaneous administration of octreotide LAR instead of intramuscular administration in patients with metastatic gastroenteropancreatic neuroendocrine tumors.
Krishnan T; Safro M; Furlanetto DM; Gill S; Solar Vasconcelos JP; Stuart HC; Martineau P; Loree JM
J Neuroendocrinol; 2024 Jan; 36(1):e13360. PubMed ID: 38088132
[TBL] [Abstract] [Full Text] [Related]
14. Efficacy and tolerability of somatostatin analogues according to gender in patients with neuroendocrine tumors.
Ruggeri RM; Aini I; Gay S; Grossrubatscher EM; Mancini C; Tarsitano MG; Zamponi V; Isidori AM; Colao A; Faggiano A;
Rev Endocr Metab Disord; 2024 Apr; 25(2):383-398. PubMed ID: 38051470
[TBL] [Abstract] [Full Text] [Related]
15. Lost in translation: evaluating the readability of online patient information for neuroendocrine tumors.
Paschke A; Grewal US
Endocrine; 2024 Apr; 84(1):97-99. PubMed ID: 38010471
[TBL] [Abstract] [Full Text] [Related]
16. Plasma-Derived Exosome Proteins as Novel Diagnostic and Prognostic Biomarkers in Neuroblastoma Patients.
Morini M; Raggi F; Bartolucci M; Petretto A; Ardito M; Rossi C; Segalerba D; Garaventa A; Eva A; Cangelosi D; Bosco MC
Cells; 2023 Oct; 12(21):. PubMed ID: 37947594
[TBL] [Abstract] [Full Text] [Related]
17. Disparity in initiation of checkpoint inhibitors among commercially insured and Medicare Advantage patients with metastatic melanoma.
Li M; Liao K; Nowakowska M; Wehner M; Shih YT
J Manag Care Spec Pharm; 2023 Nov; 29(11):1232-1241. PubMed ID: 37889870
[No Abstract] [Full Text] [Related]
18. Benefits and limitations of a dual faculty neurosurgeon approach to resection of pediatric craniopharyngioma.
Karsten MB; Slingerland AL; Riordan CP; Smith ER; Fehnel KP
Childs Nerv Syst; 2024 Mar; 40(3):647-653. PubMed ID: 37857860
[TBL] [Abstract] [Full Text] [Related]
19. Optimal first-line treatment strategies of systemic therapy for unresectable gastrointestinal neuroendocrine tumors based on the opinions of Japanese experts.
Honma Y; Ikeda M; Hijioka S; Matsumoto S; Ito T; Aoki T; Furuse J
Invest New Drugs; 2023 Dec; 41(6):777-786. PubMed ID: 37856005
[TBL] [Abstract] [Full Text] [Related]
20. The cycle effect quantified: reduced tumour uptake in subsequent cycles of [
Siebinga H; Hendrikx JJMA; de Vries-Huizing DMV; Huitema ADR; de Wit-van der Veen BJ
Eur J Nucl Med Mol Imaging; 2024 Feb; 51(3):820-827. PubMed ID: 37843598
[TBL] [Abstract] [Full Text] [Related]
[Next]
